CClinicalTrials.gg
CompletedNCT04735705Updated Nov 22, 2023Results posted

Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis

An interventional study of Cerviron in Vaginitis and Vulvovaginitis, sponsored by Perfect Care Distribution. Completed at 2 sites in Romania. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Perfect Care Distribution · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections.

The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora).

Participants will also evaluate the degree of satisfaction related to the use of the medical device.

Read the detailed description

Vaginitis is the general term characterizing a spectrum of disorders of the vagina caused by infection, inflammation, or changes in the normal vaginal flora. Symptoms include abnormal vaginal discharge, odour, pruritus, pain, dysuria and/or discomfort. Moreover, vaginitis is responsible for the most common problems in clinical medicine, and it is the reason cited most often for visits to obstetricians and gynecologists. In the past years, the problem of vaginitis has all too often been ignored by the medical community or regarded merely as a minor annoyance to women. According to Gardner, "Vaginitis must cause more unhappiness on earth than any other gynecologic disease. In addition to the many physical and emotional problems associated with vaginitis, the economic loss involved is of astronomic proportions." The most common causes of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Bacterial Vaginosis is the cause in 40% to 50% of cases in which a cause is identified, with vulvovaginal candidiasis accounting for 20% to 25% and trichomoniasis for 15% to 20% of cases. The standard of care currently is based on anti-infectious therapy. With the availability of complementary and alternative therapies and over-the-counter medications for vaginitis, many symptomatic women seek these products before or in addition to an evaluation by a medical provider. However, recurrence of vaginosis is frequent, and can include four or more episodes in one year.

Non-infectious cases, including atrophic, irritant, and inflammatory vaginitis, are less common and account for 5% to 10% of vaginitis cases. Obtaining a medical history alone has been shown to be insufficient for accurate diagnosis of vaginitis and can lead to the inappropriate administration of medication. Therefore, a careful history, examination, and laboratory testing to determine the etiology of vaginal symptoms are needed. Information on sexual behaviors and practices, gender of sex partners, menses, vaginal hygiene practices (e.g., douching), and self-treatment with medications should be collected.

Other causes of vaginitis There is no cause of vagini¬tis identified in up to 30% of women. These women may have a range of conditions, includ¬ing irritant or allergic vaginitis, atrophic vaginitis, or physiologic discharge. The presence of objective signs of vulvar inflammation in the absence of vaginal pathogens after laboratory testing suggests the possibility of mechanical, chemical, allergic, or other non-infectious causes of vulvovaginal signs or symptoms.

Inflammatory vagi¬nitis is an uncommon condition characterized by purulent vaginal discharge, burning, and dyspa¬reunia, and should be considered in patients with these symptoms if no infectious cause is found. Inflammatory vaginitis is associated with low estrogen levels, such as in menopausal or perimenopausal women.

Desquamative inflammatory vaginitis is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white women, that responds well to topical anti-inflammatory therapy. Long-term maintenance therapy is frequently required.

Irritant/allergic vaginitis is characterized by symptoms such as burning and soreness and signs such as vulvar erythema.

Atrophic vaginitis is an uncommon condition that occurs as a consequence of estrogen deficiency and is characterized by symptoms such as thin, clear discharge, vaginal dryness, dyspareunia, itching. An examination of the vulva can indicate inflammation and thin and friable vaginal mucosa. Risk factors contributing to atrophic vaginitis are menopause, lactation, oophorectomy, radiation therapy, chemotherapy, immunologic disorders, premature ovarian failure, endocrine disorders, and antioestrogen medications.

Aerobic vaginitis is a distinct vaginal condition, requiring different clinical management and with distinct clinical risks. (7) Aerobic vaginitis is defined by disruption in Lactobacillus dominance but is accompanied by more extreme inflammatory changes than BV and the presence of mainly aerobic enteric commensals or pathogens, including Group B Streptococcus (S. agalactiae), Enterococcus faecalis, Escherichia coli, and S. aureus. Streptococcus agalactiae (group B Streptococcus, GBS) vaginal pathogenicity is not uniformly acknowledged throughout the literature. GBS virulence for vagina was recognized in the past, as the organism has been observed to potentially cause local inflammation and discharge, as well as lactobacilli rarefaction.

Cytolitytic vaginosis is another condition which has been recently described as an entity distinct from either normal flora or bacterial vaginosis. This condition, also called Doderlein's vaginitis, has numerous, active lactobacilli damaging epithelial cells because of extreme acidity and low pH. The bare nuclei and cellular debris that are seen during microscopy, should not be mistaken for leucocytes and cocci.

Cerviron ovules® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

This is the first clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.

02

Conditions studied

  • Vaginitis and Vulvovaginitis

Keywords

  • Vaginitis
  • vaginal discharge, vaginal pH, vaginal microflora
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Adult females, aged 18 years to 65 years;
  • Subjects presenting two or more vaginal symptoms such as leucorrhoea, pruritus, burning sensation, erythema, pain, odour, dysuria, or dyspareunia;
  • Subjects with a diagnosis of either non-infectious vaginitis, or endogenous, symptomatic infection;
  • Negative for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis;
  • Subjects willing to provide signed informed consent to clinical investigation participation.

Exclusion criteria

Exclusion Criteria:

  • Subjects in menstrual period or suffering from menorrhagia;
  • Colpectomy;
  • Subjects with undiagnosed abnormal genital bleeding;
  • Subject with vulvar, vaginal or cervical cancer;
  • Known, active sexually transmitted infection (STI) in partner, as per anamnesis;
  • Subjects with HIV or other immunodeficiency;
  • Subjects with any pathology of the female reproductive organs;
  • Known allergy or hypersensitivity to the medical device ingredients;
  • Use of spermicides;
  • Use of diaphragm;
  • Concomitant topical or systemic anti-infective treatment;
  • Unable to comply with visit procedures;
  • Subjects included in other clinical investigations;
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cerviron vaginal ovules

    Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.

    Device: Cerviron

Interventions

  • DeviceCerviron

    Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

05

What researchers measure

Primary outcomes

  1. Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit

    Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.

    Time frame: 3 months

  2. Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation

    The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.

    Time frame: 3 months

Secondary outcomes

  1. Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment

    The vaginal discharge assessed by the investigator by using a score: 0=absent 1. mild: insufficient for speculum collection 2. moderate: sufficient for speculum collection 3. abundant: visible at the introitus even before speculum introduction 4. purulent, abnormal discharge: visible at the introitus even before speculum introduction

    Time frame: at 1, 2 and 3 months

  2. Number of Participants With Change in Vaginal pH Values

    Determination of pH values compared to its normal values (3.8 - 4.5)

    Time frame: at 1, 2 and 3 months

  3. Number of Participants With Change in Vaginal Microflora and Lactobacilli Count

    The change in Lactobacillus species as shown by microscopy

    Time frame: 3 months

  4. Number of Participants With Change in Vaginal Inflammation

    The change in inflammatory and parabasal cells by microscopy

    Time frame: 3 months

  5. Results in Patient Satisfaction's Scale (Likert Scale)

    The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale. The degree of satisfaction when using the medical device was assessed using a five-point Likert Scale, as very satisfied, satisfied, neutral, unsatisfied, and very unsatisfied.

    Time frame: 3 months

06

Results

Posted Nov 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneCerviron Vaginal Ovules
Started50
Completed47
Not completed3

Outcome measures

PrimaryNumber of Participants With the Same Gynaecological Conditions at the End of Treatment Visit

Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit
ParticipantsCerviron Vaginal Ovules
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit13
PrimaryRate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation

The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.

Time frame:
3 months
Reported as:
Number · AEs
Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation
AEsCerviron Vaginal Ovules
Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation3
SecondaryNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment

The vaginal discharge assessed by the investigator by using a score: 0=absent 1. mild: insufficient for speculum collection 2. moderate: sufficient for speculum collection 3. abundant: visible at the introitus even before speculum introduction 4. purulent, abnormal discharge: visible at the introitus even before speculum introduction

Time frame:
at 1, 2 and 3 months
Reported as:
Number · participants
Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment
participantsCerviron Vaginal Ovules
Absent - 1 month2
Absent - 2 months8
Absent - 3 months9
Mild - 1 month26
Mild - 2 months21
Mild - 3 months13
Moderate - 1 month19
Moderate - 2 months18
Moderate - 3 months25
Abundant - 1 month0
Abundant - 2 months0
Abundant - 3 months0
Purulent - 1 month0
Purulent - 2 months0
Purulent - 3 months0
SecondaryNumber of Participants With Change in Vaginal pH Values

Determination of pH values compared to its normal values (3.8 - 4.5)

Time frame:
at 1, 2 and 3 months
Reported as:
Number · Participants
Number of Participants With Change in Vaginal pH Values
ParticipantsCerviron Vaginal Ovules
Normal - 1 month41
Normal - 2 months44
Normal - 3 months47
Abnormal - 1 month6
Abnormal - 2 months3
Abnormal - 3 months0
SecondaryNumber of Participants With Change in Vaginal Microflora and Lactobacilli Count

The change in Lactobacillus species as shown by microscopy

Time frame:
3 months
Reported as:
Number · Participants
Number of Participants With Change in Vaginal Microflora and Lactobacilli Count
ParticipantsCerviron Vaginal Ovules
Lactobacilli present30
Leukocytes present38
Enterobact. present0
Squamous epithelial cells present0
Gardnerella vaginalis present2
Trich. vaginalis present0
Candida present2
Yeast cells and filaments present2
SecondaryNumber of Participants With Change in Vaginal Inflammation

The change in inflammatory and parabasal cells by microscopy

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants With Change in Vaginal Inflammation
ParticipantsCerviron Vaginal Ovules
Number of Participants With Change in Vaginal Inflammation32
SecondaryResults in Patient Satisfaction's Scale (Likert Scale)

The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale. The degree of satisfaction when using the medical device was assessed using a five-point Likert Scale, as very satisfied, satisfied, neutral, unsatisfied, and very unsatisfied.

Time frame:
3 months
Reported as:
Number · Participants
Results in Patient Satisfaction's Scale (Likert Scale)
ParticipantsCerviron Vaginal Ovules
Very Satisfied39
Satisfied6
Neutral2
Unsatisfied0
Very Unsatisfied0

Adverse events

Collected over During all the clinical investigation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cerviron Vaginal Ovules0/47 (0%)0/47 (0%)3/47 (6.4%)
Most frequent other events
Most frequent other events
EventCerviron Vaginal Ovules
Streptococcus infectionInfections and infestations1/47
E. Coli infectionInfections and infestations1/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cerviron Vaginal Ovules
<=18 years0
Between 18 and 65 years47
>=65 years0
Age, Continuous
Age, Continuous(Years)Cerviron Vaginal Ovules
Mean41.23 ± 10.27
Sex: Female, Male
Sex: Female, Male(Participants)Cerviron Vaginal Ovules
Female47
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cerviron Vaginal Ovules
Hispanic or Latino0
Not Hispanic or Latino47
Unknown or Not Reported0
Childbirth potential
Childbirth potential(Participants)Cerviron Vaginal Ovules
Count of participants36
Subject in menopause
Subject in menopause(Participants)Cerviron Vaginal Ovules
Count of participants9
Subject pregnant
Subject pregnant(Participants)Cerviron Vaginal Ovules
Count of participants0
History of cancer
History of cancer(Participants)Cerviron Vaginal Ovules
Count of participants2

7 further baseline measures are reported on the registry.

07

Study locations

2 sites
  • Spitalul Clinic Județean de Urgență "Pius Brinzeu"
    Timisoara, Timiș, Romania
  • Institutul National pentru Sanatatea Mamei si Copilului (INSMC) "Alessandrescu - Rusescu"
    Bucharest, Romania
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 5, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT04735705
Lead sponsor
Perfect Care Distribution
Collaborators
MDX Research
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Apr 1, 2021
Primary completion
Sep 9, 2021
Completion
Sep 9, 2021
Results posted
Nov 22, 2023
Last update
Nov 22, 2023

Study contacts

Ramona Petrita, CSO
study director · MDX Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion